WUXI BIOLOGICS-00000083

Research WUXI BIOLOGICS-00000083 (1FW2) on Bullrun: market cap EUR 22.17B, P/E 36.0. Explore financials, valuation history, model signals, and stock context.

Key Metrics

Valuation Snapshot

latest market cap is EUR 22.17B; P/E is 36.0.

Peer valuation comparison

Latest P/E is 36x versus a Healthcare sector median of 24.46x (47.2% above).

Latest P/E is 36x versus a China median of 10.67x (237.3% above).

Five-year financial history

YearRevenueNet incomeFree cash flowGross marginDiluted EPSCashTotal debtEquity
FY2025CNY 21.79BCNY 4.91BCNY 2.61B46.0%1.16CNY 9.21BCNY 3.10BCNY 47.25B
FY2024CNY 18.68BCNY 3.36BCNY 1.29B41.0%0.78CNY 8.28BCNY 4.94BCNY 41.82B
FY2023CNY 17.03BCNY 3.40BCNY 437.20M40.1%0.77CNY 9.67BCNY 4.56BCNY 40.33B
FY2022CNY 15.27BCNY 4.42B-CNY 326.72M44.0%1.01CNY 6.40BCNY 4.42BCNY 35.05B
FY2021CNY 10.29BCNY 3.39B-CNY 3.09B46.9%0.77CNY 9.00BCNY 4.30BCNY 32.28B

Valuation history

YearSnapshot dateMarket capP/EDividend yieldAnnual dividend/share
20262026-08-27EUR 22.17B36.0n/a0

Dividend history

Latest trailing dividend snapshot: annual dividend/share 0 EUR.

About WUXI BIOLOGICS-00000083

WuXi Biologics (Cayman) Inc., an investment holding company, provides end-to-end solutions and services for biologics discovery, development, and manufacturing for biologics industry in the People's Republic of China, North America, Europe, Singapore, Japan, South Korea, Australia, and Brazil. It operates through two segments: Biologics and XDC.

Related stock research

Other Healthcare stocks

Frequently asked questions

What is WUXI BIOLOGICS-00000083's market cap?

WUXI BIOLOGICS-00000083's market capitalization is EUR 22.17B.

What is WUXI BIOLOGICS-00000083's P/E ratio?

WUXI BIOLOGICS-00000083's price-to-earnings (P/E) ratio is 36.0.

What does WUXI BIOLOGICS-00000083 do?

WuXi Biologics (Cayman) Inc., an investment holding company, provides end-to-end solutions and services for biologics discovery, development, and manufacturing for biologics industry in the People's Republic of China, North America, Europe, Singapore, Japan, South Korea, Australia, and Brazil. It operates through two segments: Biologics and XDC.